Phase I study of <scp>OPB</scp>‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

Michinori Ogura, Kiyohiko Hatake|Cancer Science|2015

Cited by 101